Galecto Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. MacroGenics Gets $40m Up Front For St

Sweden's Vicore Pharma can now boast Sanofi as a backer as it kicks off mid-stage trials of its idiopathic pulmonary fibrosis (IPF) candidate, buloxibutid. The French drugmaker has committed to s

The number of biopharmaceutical companies that have gone public in the US in 2024 has now beat the 2023 total of 21 with the 10 October initial public offerings by Upstream Bio Inc. and CAMP4 Thera

Idiopathic pulmonary fibrosis (IPF) has proved to be a tough disease to crack, as last year’s trial failures from Galecto Inc. and FibroGen, Inc. have shown. But Boehringer Ingelheim GmbH has de